Prof Matt Sydes speaks to ecancer at the 2020 ASCO GU meeting in San Francisco.
He explains the importance of contextualising statistical data to identify clinically relevant results and addresses the debate of clinical significance versus statistical significance.
Prof Sydes describes the interpretation of the radiotherapy comparison conducted in patients with metastatic prostate cancer in the STAMPEDE trial.
He also explains how to carry out an accurate sample size calculation and how to choose the right outcome measures for prostate cancer trials.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
|Clinical significance versus statistical significance|
|The STAMPEDE trial|
|The HORRAD trial|
|Calculating sample size|
|Choosing the right outcome measures|
|The COMET initiative|
|Investigating the combination of zoledronic acid and celecoxib in the STAMPEDE trial|